Home > Compound List > Compound details
119302-91-9 molecular structure
click picture or here to close

1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-14-(acetyloxy)-5-hydroxy-2,15-dimethyl-4-(morpholin-4-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-(prop-2-en-1-yl)pyrrolidin-1-ium

ChemBase ID: 609
Molecular Formular: C32H53N2O4+
Molecular Mass: 529.77422
Monoisotopic Mass: 529.40053319
SMILES and InChIs

SMILES:
O([C@@H]1[C@@]2([C@H]([C@H]3[C@@H]([C@@]4([C@@H](CC3)C[C@H](O)[C@@H](N3CCOCC3)C4)C)CC2)C[C@@H]1[N+]1(CCCC1)CC=C)C)C(=O)C
Canonical SMILES:
C=CC[N+]1(CCCC1)[C@H]1C[C@@H]2[C@]([C@H]1OC(=O)C)(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C[C@@H]([C@H](C2)O)N1CCOCC1
InChI:
InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1
InChIKey:
YXRDKMPIGHSVRX-OOJCLDBCSA-N

Cite this record

CBID:609 http://www.chembase.cn/molecule-609.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-14-(acetyloxy)-5-hydroxy-2,15-dimethyl-4-(morpholin-4-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-(prop-2-en-1-yl)pyrrolidin-1-ium
IUPAC Traditional name
rocuronium
Brand Name
Rocuronium bromide
Zemuron
Synonyms
Rocuronium
CAS Number
119302-91-9
PubChem SID
160964072
46506855
PubChem CID
441290

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem ALOGPS 2.1
Acid pKa 14.585371  H Acceptors
H Donor LogD (pH = 5.5) -2.7576323 
LogD (pH = 7.4) -0.99869245  Log P -0.33122167 
Molar Refractivity 161.6511 cm3 Polarizability 60.11785 Å3
Polar Surface Area 59.0 Å2 Rotatable Bonds
Lipinski's Rule of Five false 
Log P 2.71  LOG S -7.3 
Solubility (Water) 2.84e-05 g/l 

PROPERTIES

PROPERTIES

Physical Property Bioassay(PubChem)
Solubility
Complete expand Show data source

DETAILS

DETAILS

DrugBank DrugBank
DrugBank - DB00728 external link
Item Information
Drug Groups approved
Description Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is marketed under the trade name of Zemuron in the United States and Esmeron in most other countries.
There is considered to be a risk of allergic reaction to the drug in some patients (particularly those with asthma), but a similar incidence of allergic reactions has been observed by using other members of the same drug class (non-depolarizing neuromuscular blocking drugs). The γ-cyclodextrin derivative sugammadex (trade name Bridion) has been recently introduced as a novel agent to reverse the action of rocuronium.
Indication For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Pharmacology Neuromuscular blocking agents are drugs that cause skeletal muscle relaxation primarily by causing a decreased response to the neurotransmitter acetylcholine (ACh) at the myoneural (neuromuscular) junction of skeletal muscle. At that site, ACh normally produces electrical depolarization of the postjunctional membrane of motor end-plate, which leads to conduction of muscle action potential and subsequently induces skeletal muscle contraction. Neuromuscular agents are classified as depolarizing or nondepolarizing. Rocuronium is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium, like vecuronium is longer acting in infants than in children. However, unlike vecuronium, rocuronium retains the characteristics of an intermediate-acting NMBD in infants.
Toxicity No cases of significant accidental or intentional overdose have been reported. Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
Affected Organisms
Humans and other mammals
Biotransformation Rocuronium is metabolized to a less active metabolite, 17-desacetyl-rocuronium, and is eliminated primarily by the liver.
Absorption Poorly absorbed from the GI tract.
Half Life The rapid distribution half-life is 1-2 minutes and the slower distribution half-life is 14-18 minutes. Renal impairment has no net effect on half-life, however, half-life is almost doubled in patients with impaired liver function.
Protein Binding Approximately 30% bound to human plasma proteins.
Elimination Studies of distribution, metabolism, and excretion in cats and dogs indicate that rocuronium is eliminated primarily by the liver.
Distribution * 0.3 L/kg [3 to <12 mos]
* 0.26 L/kg [1 to <3 yrs]
* 0.21 L/kg [3 to <8 yrs]
Clearance * 0.25 L/kg/hr [Adults (Ages 27 to 58 years)]
* 0.21 L/kg/hr [Geriatrics (>=65 yrs)]
* 0.16 L/kg/hr [Normal ewnal and hepatice function]
* 0.13 L/kg/hr [Renal transplant patients]
* 0.13 L/kg/hr [Hepatic dysfunction patients]
* 0.35 +/- 0.08 L/kg/hr [Pediatric Patients 3 to <12 mos]
* 0.32 +/- 0.07 L/kg/hr [Pediatric Patients 1 to 3 yrs]
* 0.44 +/- 0.16 L/kg/hr [Pediatric Patients 3 to 8 yrs]
References
Agoston S, Vandenbrom RH, Wierda JM: Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet. 1992 Feb;22(2):94-115. [Pubmed]
Khuenl-Brady KS, Sparr H: Clinical pharmacokinetics of rocuronium bromide. Clin Pharmacokinet. 1996 Sep;31(3):174-83. [Pubmed]
Alvarez-Gomez JA: [Rocuronium] Rev Esp Anestesiol Reanim. 1997 Oct;44(8):310-4. [Pubmed]
Wicks TC: The pharmacology of rocuronium bromide (ORG 9426). AANA J. 1994 Feb;62(1):33-8. [Pubmed]
Sparr HJ, Beaufort TM, Fuchs-Buder T: Newer neuromuscular blocking agents: how do they compare with established agents? Drugs. 2001;61(7):919-42. [Pubmed]
Hemmerling TM, Russo G, Bracco D: Neuromuscular blockade in cardiac surgery: an update for clinicians. Ann Card Anaesth. 2008 Jul-Dec;11(2):80-90. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • • Alvarez-Gomez JA: [Rocuronium] Rev Esp Anestesiol Reanim. 1997 Oct;44(8):310-4. Pubmed
  • • Wicks TC: The pharmacology of rocuronium bromide (ORG 9426). AANA J. 1994 Feb;62(1):33-8. Pubmed
  • • Agoston S, Vandenbrom RH, Wierda JM: Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet. 1992 Feb;22(2):94-115. Pubmed
  • • Khuenl-Brady KS, Sparr H: Clinical pharmacokinetics of rocuronium bromide. Clin Pharmacokinet. 1996 Sep;31(3):174-83. Pubmed
  • • Sparr HJ, Beaufort TM, Fuchs-Buder T: Newer neuromuscular blocking agents: how do they compare with established agents? Drugs. 2001;61(7):919-42. Pubmed
  • • Hemmerling TM, Russo G, Bracco D: Neuromuscular blockade in cardiac surgery: an update for clinicians. Ann Card Anaesth. 2008 Jul-Dec;11(2):80-90. Pubmed
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle